Todd Usen - 06 Mar 2026 Form 4 Insider Report for Adagio Medical Holdings, Inc. (ADGM)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ADGM
Reported as of: 06 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Mar 2026, 06:00:46 UTC
Prior SEC filing: 15 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Todd Usen

Key filing fact

Todd Usen filed Form 4 for Adagio Medical Holdings, Inc. (ADGM) on 09 Mar 2026.

Key facts

This page summarizes Todd Usen's Form 4 filing for Adagio Medical Holdings, Inc. (ADGM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Mar 2026, 06:00.

Change

Previous filing in this sequence was filed on 15 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001964615 Primary reporting owner

Usen Todd

Relationship: Chief Executive Officer, Director
Address: C/O ADAGIO MEDICAL HOLDINGS, INC., 26051 MERIT CIRCLE, SUITE 102, LAGUNA HILLS
Signature: /s/ Todd Usen
Signature date: 09 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADGM transaction Derivative

Employee Stock Options (Right to Buy)

Award

Transaction value
Shares: +800,000
Change %
Price: $0.000000^*
Shares after: 800,000
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 800,000
Exercise price: $0.9770
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Employee Stock Options granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest over a four-year period, whereby twenty-five percent (25%) of the Option will vest on March 6, 2027, with the remaining shares subject to the Option vesting in thirty-six (36) equal monthly installments thereafter.